Literature DB >> 6119414

Hepatic encephalopathy and the gamma-aminobutyric-acid neurotransmitter system.

D F Schafer, E A Jones.   

Abstract

gamma-Aminobutyric acid (GABA), the principal inhibitory neurotransmitter of the mammalian brain, is synthesised by gut bacteria. In a rabbit model the development of hepatic encephalopathy was associated with increased levels of GABA in plasma, increased permeability of the blood-brain barrier, increased numbers of binding-sites for GABA and benzodiazepines in the brain, and a pattern of neural activity similar to that induced by drugs which activate the GABA neurotransmitter system. It is postulated that in liver failure gut-derived GABA passes through a permeable blood-brain barrier and induces its own receptors in the brain, that gut-derived GABA contributes to the neural inhibition of hepatic encephalopathy, and that an increased number of drug-binding sites mediates enhanced sensitivity to barbiturates and benzodiazepines in liver failure.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6119414     DOI: 10.1016/s0140-6736(82)92559-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  44 in total

Review 1.  Animal models of acute hepatic failure.

Authors:  T M Rahman; H J Hodgson
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

Review 2.  Pathogenesis and treatment of portal-systemic encephalopathy: an update.

Authors:  R F Butterworth
Journal:  Dig Dis Sci       Date:  1992-03       Impact factor: 3.199

Review 3.  Does ammonia contribute to increased GABA-ergic neurotransmission in liver failure?

Authors:  E A Jones; A S Basile
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

4.  Regional brain GABA metabolism and release during hepatic coma produced in rats chronically treated with carbon tetrachloride.

Authors:  M Díaz-Muñoz; R Tapia
Journal:  Neurochem Res       Date:  1988-01       Impact factor: 3.996

Review 5.  Neurochemistry of hepatic encephalopathy.

Authors:  C O Record
Journal:  Gut       Date:  1991-11       Impact factor: 23.059

6.  Activities of neuronal and astrocytic marker enzymes in autopsied brain tissue from patients with hepatic encephalopathy.

Authors:  J Lavoie; J F Giguère; G P Layrargues; R F Butterworth
Journal:  Metab Brain Dis       Date:  1987-12       Impact factor: 3.584

7.  Reduced stents and stent-grafts for the management of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation.

Authors:  David C Madoff; Michael J Wallace
Journal:  Semin Intervent Radiol       Date:  2005-12       Impact factor: 1.513

8.  Evidence for the presence of a benzodiazepine receptor binding substance in cerebrospinal fluid of a rabbit model of hepatic encephalopathy.

Authors:  K D Mullen; J V Martin; W B Mendelson; K Kaminsky-Russ; E A Jones
Journal:  Metab Brain Dis       Date:  1989-12       Impact factor: 3.584

9.  Nitroarginine, an inhibitor of nitric oxide synthetase, attenuates ammonia toxicity and ammonia-induced alterations in brain metabolism.

Authors:  E Kosenko; Y Kaminsky; E Grau; M D Miñana; S Grisolía; V Felipo
Journal:  Neurochem Res       Date:  1995-04       Impact factor: 3.996

10.  Pannexin1 as a novel cerebral target in pathogenesis of hepatic encephalopathy.

Authors:  Papia Mondal; Surendra Kumar Trigun
Journal:  Metab Brain Dis       Date:  2014-05-08       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.